These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1082 related articles for article (PubMed ID: 24008862)

  • 1. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.
    Cortes-Dericks L; Galetta D; Spaggiari L; Schmid RA; Karoubi G
    Eur J Cardiothorac Surg; 2012 Jun; 41(6):e173-81. PubMed ID: 22529186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
    Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
    Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
    Roudi R; Korourian A; Shariftabrizi A; Madjd Z
    Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
    Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
    Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
    Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
    Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.
    Huang M; Zhu H; Feng J; Ni S; Huang J
    Dis Markers; 2015; 2015():986095. PubMed ID: 25691807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.
    Bertolini G; Roz L; Perego P; Tortoreto M; Fontanella E; Gatti L; Pratesi G; Fabbri A; Andriani F; Tinelli S; Roz E; Caserini R; Lo Vullo S; Camerini T; Mariani L; Delia D; Calabrò E; Pastorino U; Sozzi G
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16281-6. PubMed ID: 19805294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.
    Cui F; Wang J; Chen D; Chen YJ
    Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathobiological implications of MUC4 in non-small-cell lung cancer.
    Majhi PD; Lakshmanan I; Ponnusamy MP; Jain M; Das S; Kaur S; Shimizu ST; West WW; Johansson SL; Smith LM; Yu F; Rolle CE; Sharma P; Carey GB; Batra SK; Ganti AK
    J Thorac Oncol; 2013 Apr; 8(4):398-407. PubMed ID: 23370366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.
    Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
    Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.
    Zhou X; Li D; Wang X; Zhang B; Zhu H; Zhao J
    Oncotarget; 2015 Feb; 6(5):3111-22. PubMed ID: 25605013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
    Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
    Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
    Zhang Z; Guo Y
    Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
    Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
    Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
    Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.